Emergent Biosolutions (EBS)
(Delayed Data from NYSE)
$9.35 USD
+0.41 (4.59%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $9.23 -0.12 (-1.28%) 7:58 PM ET
2-Buy of 5 2
B Value C Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$9.35 USD
+0.41 (4.59%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $9.23 -0.12 (-1.28%) 7:58 PM ET
2-Buy of 5 2
B Value C Growth F Momentum D VGM
Zacks News
Should You Invest in the Invesco SP SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
Axsome Focuses on Filling NDAs for Two CNS Candidates in 2020
by Zacks Equity Research
Axsome's (AXSM) CNS pipeline candidates are advancing well. NDAs for AXS-05 to address MDD and AXS-07 as an acute treatment of migraine will be filed in Q4. Lack of a marketed product is a concern.
Ceylad Gets FDA Nod to Begin Phase I Study on CAR T Candidate
by Zacks Equity Research
Celyad (CYAD) gets the FDA's permission to begin a phase I study on its lead CAR T candidate, CYAD-211, for the treatment of relapsed/refractory multiple myeloma.
Zacks.com featured highlights include: Nautilus, Ameresco, Canadian Solar, Emergent BioSolutions and Pacira BioSciences
by Zacks Equity Research
Zacks.com featured highlights include: Nautilus, Ameresco, Canadian Solar, Emergent BioSolutions and Pacira BioSciences
Blueprint Medicines, Roche to Develop Pralsetinib for Cancer
by Zacks Equity Research
Blueprint Medicines (BPMC) signs a contract with Roche to commercialize pralsetinib for treating patients with RET-fusion NSCLC, RET-mutant MTC, other thyroid cancers and other solid tumors.
Axsome's NDA for Depressive Disorder Drug on Track in Q420
by Zacks Equity Research
Axsome (AXSM) concludes a favorable pre-NDA meeting with the FDA officials for AXS-05 to treat major depressive disorder. The company is on course to file the NDA in Q4.
FDA Grants Extra Access to Vanda's Tradipitant to a Patient
by Zacks Equity Research
Vanda (VNDA) gets authorization from the FDA for expanded access to tradipitant for a single patient for six more months.
5 Stocks With Recent Price Strength Despite Market Volatility
by Nalak Das
Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.
Emergent Biosolutions (EBS) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Emergent Biosolutions (EBS) closed at $94.23 in the latest trading session, marking a -0.26% move from the prior day.
AbbVie (ABBV) Gets FDA Nod for Another Botox Label Expansion
by Zacks Equity Research
AbbVie (ABBV) wins the FDA nod for an expanded use of Botox to treat spasticity in pediatric patients aged two years and above including those with lower limb spasticity caused by cerebral palsy.
Is Emergent Biosolutions (EBS) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (EBS) Outperforming Other Medical Stocks This Year?
Emergent (EBS) Stock Up Year to Date on Coronavirus Vaccine Deals
by Zacks Equity Research
Emergent (EBS) inks deals with multiple companies to provide manufacturing services for helping them develop COVID-19 vaccine.
Abeona Restarts Enrollment in Connective Tissue Disorder Study
by Zacks Equity Research
Abeona (ABEO) restarts patient enrollment in phase III VIITAL study of EB-101 for the treatment of recessive dystrophic epidermolysis bullosa.
6 Stocks to Wade Through the Spike in Coronavirus Cases
by Sreoshi Bera
The current health scare drives market volatility and calls for investment in consumer staples, healthcare and IT sectors for stable returns.
Emergent's (EBS) 5-Year Deal to Back J&J's Coronavirus Vaccine
by Zacks Equity Research
Emergent BioSolutions (EBS) extends a five-year deal with J&J to provide its CDMO services to produce the drug substance of the latter's COVID-19 vaccine candidate. Shares rise.
Will Emergent BioSolutions' Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Emergent BioSolutions
AbbVie (ABBV) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
AbbVie (ABBV) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Blueprint Medicines Files NDA to FDA for Pralsetinib in MTC
by Zacks Equity Research
Blueprint Medicines (BPMC) files an NDA to the FDA for pralsetinib to treat patients with advanced/metastatic RET mutant medullary thyroid cancer and RET fusion-positive thyroid cancers. Stock up.
Amgen (AMGN) Looks Good: Stock Adds 8.2% in Session
by Zacks Equity Research
Amgen (AMGN) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
Ultragenyx (RARE) Looks Good: Stock Adds 8.2% in Session
by Zacks Equity Research
Ultragenyx (RARE) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
Ultragenyx's Dojolvi Gets FDA Nod to Treat Rare Disease
by Zacks Equity Research
Ultragenyx (RARE) gets FDA approval forDojolvi for the treatment of pediatric and adult patients with molecularly confirmed long-chain fatty acid oxidation disorders.
Akero Therapeutics (AKRO) Jumps: Stock Rises 8.9%
by Zacks Equity Research
Akero Therapeutics (AKRO) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Eidos Therapeutics (EIDX) Looks Good: Stock Adds 6.4% in Session
by Zacks Equity Research
Eidos Therapeutics (EIDX) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
3 Reasons Why Emergent Biosolutions (EBS) Is a Great Growth Stock
by Zacks Equity Research
Emergent Biosolutions (EBS) could produce exceptional returns because of its solid growth attributes.
Ascendis Submits BLA to FDA for TransConhGH in Pediatric GHD
by Zacks Equity Research
Ascendis Pharma (ASND) submits BLA to the FDA for TransConhGH for the treatment of pediatric growth hormone deficiency.